Polen Capital Management
CORT icon

Polen Capital Management’s Corcept Therapeutics CORT Stock Holding History

Polen Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,363
Closed -$2.36M – 251
2025
Q3 		$2.36M Buy
28,363
+6,787
+31% +$491K 0.01% 92
2025
Q2 		$1.58M Buy
+21,576
New +$1.56M ﹤0.01% 101

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Polen Capital Management's CORT Position: Q4 2025 in Review

Polen Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 28,363 shares — an estimated $2.36M sold.

Polen Capital Management first reported a position in CORT in Q2 2025 and held it in 2 quarters. The position peaked at $2.36M in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Polen Capital Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Polen Capital Management sold 28,363 Corcept Therapeutics shares in Q4 2025, an estimated $2.36M.
  • Polen Capital Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 2 quarters.
  • Polen Capital Management's Corcept Therapeutics position peaked at $2.36M in Q3 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Polen Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.